Alumis Inc (ALMS)

$8.30 +0.46 (5.87%)
Market Cap 773.55M
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,266,800
Avg Vol 854,578
Day's Range N/A - N/A
Shares Out 104.39M
Stochastic %K 90%
Beta -1.87
Analysts Strong Sell
Price Target $19.00

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
10xby3
10xby3 Dec. 5 at 2:29 PM
$SLV $ALMS $ALLO $CHRS full force!
0 · Reply
kubota2323
kubota2323 Dec. 5 at 2:18 PM
$ALMS welp
0 · Reply
10xby3
10xby3 Dec. 5 at 1:22 PM
$ALMS niner incoming - I love that nobody has this on their radar!
0 · Reply
10xby3
10xby3 Dec. 5 at 1:19 PM
$ALMS only what ~30 trading days before data release. This is fun, and that is the takeout window: pay $1.5-2 billion now or $4 plus after readout. My opinion is $14-16 a share before xmas.
0 · Reply
neslo12
neslo12 Dec. 5 at 3:53 AM
$ALMS I bought in to this stock because of inside trading.. I have done some research.. and still.... what, why, how is this stock going up?
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 5 at 1:59 AM
$ALMS follow the mf money.
1 · Reply
ELNINA
ELNINA Dec. 5 at 1:24 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 38,702 +5.59% $ 7.64 730,499 Nov 28, 2025 Dec 3, 2025 10:06 PM
0 · Reply
ELNINA
ELNINA Dec. 5 at 1:24 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 86,350 +11.82% $ 7.46 816,849 Dec 01, 2025 Dec 3, 2025 10:06 PM
0 · Reply
ELNINA
ELNINA Dec. 5 at 1:24 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 96,000 +11.75% $ 7.55 912,849 Dec 02, 2025 Dec 4, 2025 9:11 PM
0 · Reply
ELNINA
ELNINA Dec. 5 at 1:23 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 100,000 +10.95% $ 7.75 1,012,849 Dec 03, 2025 Dec 4, 2025 9:11 PM
0 · Reply
Latest News on ALMS
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 21 days ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Sep 17, 2025, 4:53 AM EDT - 2 months ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 3 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 4 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 5 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 6 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 6 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 7 months ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 7 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 7 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 8 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 8 months ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 8 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 8 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 8 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 9 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 9 months ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 9 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 9 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 9 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 9 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 10 months ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 10 months ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 10 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 10 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 10 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 11 months ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

Jul 1, 2024, 11:51 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 1:36 PM EDT - 1 year ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 1 year ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 1 year ago

Alumis Announces Pricing of Initial Public Offering

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 1 year ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 1 year ago

Alumis eyes $300 million in proceeds in IPO

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

Jun 11, 2024, 12:25 PM EDT - 1 year ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

10xby3
10xby3 Dec. 5 at 2:29 PM
$SLV $ALMS $ALLO $CHRS full force!
0 · Reply
kubota2323
kubota2323 Dec. 5 at 2:18 PM
$ALMS welp
0 · Reply
10xby3
10xby3 Dec. 5 at 1:22 PM
$ALMS niner incoming - I love that nobody has this on their radar!
0 · Reply
10xby3
10xby3 Dec. 5 at 1:19 PM
$ALMS only what ~30 trading days before data release. This is fun, and that is the takeout window: pay $1.5-2 billion now or $4 plus after readout. My opinion is $14-16 a share before xmas.
0 · Reply
neslo12
neslo12 Dec. 5 at 3:53 AM
$ALMS I bought in to this stock because of inside trading.. I have done some research.. and still.... what, why, how is this stock going up?
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 5 at 1:59 AM
$ALMS follow the mf money.
1 · Reply
ELNINA
ELNINA Dec. 5 at 1:24 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 38,702 +5.59% $ 7.64 730,499 Nov 28, 2025 Dec 3, 2025 10:06 PM
0 · Reply
ELNINA
ELNINA Dec. 5 at 1:24 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 86,350 +11.82% $ 7.46 816,849 Dec 01, 2025 Dec 3, 2025 10:06 PM
0 · Reply
ELNINA
ELNINA Dec. 5 at 1:24 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 96,000 +11.75% $ 7.55 912,849 Dec 02, 2025 Dec 4, 2025 9:11 PM
0 · Reply
ELNINA
ELNINA Dec. 5 at 1:23 AM
$ALMS AKKARAJU SRINIVAS Not Specified Purchase 100,000 +10.95% $ 7.75 1,012,849 Dec 03, 2025 Dec 4, 2025 9:11 PM
0 · Reply
ELNINA
ELNINA Dec. 5 at 1:23 AM
$ALMS AKKARAJU SRINIVAS Purchase 66,027 $ 8.18 total 1,078,876 Dec 04, 2025 bought Dec 4, 2025 9:11 PM
0 · Reply
10xby3
10xby3 Dec. 4 at 8:48 PM
$ALMS new high for the year tmrw? runner! Silver and this look so tasty to move higher, just getting started.
0 · Reply
24oldmillclear
24oldmillclear Dec. 4 at 8:11 PM
$ALMS
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 7:20 PM
$ALMS Share Price: $8.09 Contract Selected: Jul 17, 2026 $3.0 Calls Buy Zone: $2.55 – $3.15 Target Zone: $4.67 – $5.71 Potential Upside: 73% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Piloto909
Piloto909 Dec. 4 at 4:16 PM
$ALMS not even 500 watching this stock. People don’t even know about this one yet, but they will. Can’t wait for data on this one…
1 · Reply
10xby3
10xby3 Dec. 4 at 3:38 PM
$ALMS data soon - somebody knows something. could explode past my niner today!
0 · Reply
10xby3
10xby3 Dec. 4 at 3:11 PM
$ALMS gimme niner
0 · Reply
BlackHillsTrader
BlackHillsTrader Dec. 4 at 1:39 PM
$CAPR Just took a large position here after BIG NEWS. Shorts are hosed! $ALMS $XERS $OPEN
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 4 at 5:42 AM
$XERS $ALMS ALMS has a very impressive piepline that has 10-12b mc written all over it given the TAM. I think they can attract enough attention q1 2026 with P3 results to get to 25-30 range. 2026 and 2027 will be very busy with serial catalysts and 50 is not out of the question. Step 1, waiting for p3 data which is due next 1-2 months. Xers I am not too familiar will deep dive it this week.
0 · Reply
ChazzyTrades
ChazzyTrades Dec. 4 at 4:46 AM
$ALMS 🚀🚀
0 · Reply
HedgeFollow
HedgeFollow Dec. 3 at 8:18 PM
Largest Insider Buys in the past week: $DASH, $NEXT, $GRND, $FI & $ALMS Source: https://hedgefollow.com/largest-insider-buys.php
1 · Reply
10xby3
10xby3 Dec. 3 at 7:11 PM
$ALMS niner coming!
0 · Reply